Title | |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Goyal P, Anderson TS, Bernacki GM, Marcum ZA, Orkaby AR, Kim D, Zullo A, Krishnaswami A, Weissman A, Steinman MA, Rich MW |
Journal | J Am Geriatr Soc |
Volume | 68 |
Issue | 1 |
Pagination | 78-86 |
Date Published | 2020 01 |
ISSN | 1532-5415 |
Keywords | Aged, Cardiologists, Cardiovascular Agents, Cardiovascular Diseases, Chronic Disease, Cross-Sectional Studies, Deprescriptions, Drug-Related Side Effects and Adverse Reactions, Female, Frail Elderly, Geriatricians, Humans, Life Expectancy, Male, Surveys and Questionnaires, United States |
Abstract | BACKGROUND/OBJECTIVES: Guideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties. DESIGN: National cross-sectional survey. SETTING: Ambulatory. PARTICIPANTS: Random sample of geriatricians, general internists, and cardiologists from the American College of Physicians. MEASUREMENTS: Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases. RESULTS: In each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P CONCLUSIONS: While barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019. |
DOI | 10.1111/jgs.16157 |
Alternate Journal | J Am Geriatr Soc |
PubMed ID | 31509233 |
PubMed Central ID | PMC7061460 |
Grant List | K12 HS022982 / HS / AHRQ HHS / United States IK2 CX001800 / CX / CSRD VA / United States R03 AG056446 / AG / NIA NIH HHS / United States L30 AG060521 / AG / NIA NIH HHS / United States R24 AG064025 / AG / NIA NIH HHS / United States T32HP19025-14 / / National Research Service Award training / International K24 AG049057 / AG / NIA NIH HHS / United States R03 AG060169 / AG / NIA NIH HHS / United States U13 AG047008 / AG / NIA NIH HHS / United States P30 AG044281 / AG / NIA NIH HHS / United States R03 AG064373 / AG / NIA NIH HHS / United States L30 AG060493 / AG / NIA NIH HHS / United States K76 AG059929 / AG / NIA NIH HHS / United States |